Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26764345 | 1.00 | EPHX1 (0.49) | EPHX1EPHX2ALDH1A1TP53FAAH | |
| SCHEMBL26633751 | 0.89 | SMN1; SMN2 (0.50) | EPHX2ALDH1A1FAAHKMT2APKM | |
| SCHEMBL26633905 | 0.88 | L3MBTL1 (0.49) | EPHX1ALDH1A1TP53KMT2AMEN1 | |
| SCHEMBL24011303 | 0.86 | ALDH1A1 (0.59) | EPHX1EPHX2ALDH1A1FAAHKMT2A | |
| SCHEMBL26764348 | 0.83 | FBP1 (0.52) | EPHX1EPHX2ALDH1A1TP53KMT2A | |
| SCHEMBL30306707 | 0.83 | FBP1 (0.52) | EPHX1EPHX2ALDH1A1TP53KMT2A | |
| SCHEMBL26633928 | 0.76 | EPHX1 (0.50) | EPHX1ALDH1A1TP53KMT2APKM | |
| SCHEMBL24011378 | 0.76 | SMN1; SMN2 (0.58) | EPHX2ALDH1A1FAAHKMT2APKM | |
| SCHEMBL26633744 | 0.75 | EPHX1 (0.54) | EPHX1ALDH1A1TP53KMT2APKM | |
| SCHEMBL24011369 | 0.75 | L3MBTL1 (0.55) | EPHX1ALDH1A1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843295-B | NAMPT modulators | 赛特凯恩蒂克公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-115843295-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | EPHX1 3913/4885EPHX2 4418/4885ALDH1A1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.